The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases
Open accessAbstract
Objective: To assess the impact of somatic gene mutations on survival among patients undergoing resection of colorectal liver metastases (CLM). Background: Patients undergoing CLM resection have heterogeneous outcomes, and accurate risk stratification is necessary to optimize patient selection for surgery. Methods: Next-generation sequencing of 50 cancer-related genes was performed from primary tumors and/or liver metastases in 401 patients undergoing CLM resection. Missense TP53 mutations were classified by the evolutionary action score (EAp53)—a novel approach that dichotomizes mutations as low or high risk. Results: The most frequent somatic gene mutations were TP53 (65.6%), followed by KRAS (48.1%) and APC (47.4%). Double mutation in RAS/TP53, identified in 31.4% of patients, was correlated with primary tumor location in the right colon (P = 0.006). On multivariable analysis, RAS/TP53 double mutation was an independent predictor of shorter overall survival (hazard ratio 2.62, 95% confidence interval 1.41–4.87, P = 0.002). In patients with co-mutated RAS, EAp53 high-risk mutations were associated with shorter 5-year overall survival of 12.2%, compared with 55.7% for TP53 wild type (P < 0.001). The negative prognostic effects of RAS and TP53 mutations were limited to tumors harboring mutations in both genes. Conclusions: Concomitant RAS and TP53 mutations are associated with decreased survival after CLM resection. A high EAp53 predicts a subset of patients with worse prognosis. These preliminary analyses suggest that surgical resection of liver metastases should be carefully considered in this subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · cited 1×
“Since 2012, metastatic colorectal cancer samples submitted for KRAS and/or BRAF testing are routinely analyzed by nextgeneration sequencing to detect somatic mutations in the coding sequence of 50 genes from DNA extracted from formalin-fixed paraffin-embedded tumor samples, as previously described.(20) Sequence analys…”
Self-citationKatsonis, P., & Lichtarge, O. (2014) · Genome Research · doi:10.1101/gr.176214.114 · Cited by 137 · cited 3×
“To identify potentially nondeleterious TP53 mutations, we classified mutations as truncating and missense, and further stratified missense mutations by EAp53, which is based upon the evolutionary importance of a mutation site and the relative odds of an amino acid substitution.(16) EAp53 was previously shown to strati…”
InfluentialSelf-citation
Research works printed but not linked: 27
- Abdalla, 2004, Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases, Ann Surg, 239, 818, 10.1097/01.sla.0000128305.90650.71 · DOI · Paper page
- Passot, 2017, Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection, Surgery, 161, 332, 10.1016/j.surg.2016.07.032 · DOI
- Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 371, 1609, 10.1056/NEJMoa1403108 · DOI · Paper page
- de Rosa, 2016, DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics, J Clin Oncol, 34, 3039, 10.1200/JCO.2016.66.6826 · DOI
- Haddad, 2004, Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases, Ann Surg Oncol, 11, 977, 10.1245/ASO.2004.03.585 · DOI
- Schirripa, 2015, BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection, Br J Cancer, 112, 1921, 10.1038/bjc.2015.142 · DOI · Paper page
- Vauthey, 2013, RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases, Ann Surg, 258, 619, 10.1097/SLA.0b013e3182a5025a · DOI · Paper page
- Kemeny, 2014, KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases, Cancer, 120, 3965, 10.1002/cncr.28954 · DOI
- Brudvik, 2016, RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases, Ann Surg Oncol, 23, 2635, 10.1245/s10434-016-5187-2 · DOI
- Conlin, 2005, The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, 54, 1283, 10.1136/gut.2005.066514 · DOI · Paper page
- Rosty, 2001, Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival, Int J Cancer, 95, 162, 10.1002/1097-0215(20010520)95:3<162::AID-IJC1028>3.0.CO;2-J · doi:10.1002/1097-0215(20010520)95:3<162::aid-ijc1028>3.0.co;2-j
- Pilat, 2015, Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study, Eur J Surg Oncol, 41, 683, 10.1016/j.ejso.2015.02.003 · DOI
- McMurray, 2008, Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype, Nature, 453, 1112, 10.1038/nature06973 · DOI · Paper page
- Parada, 1984, Cooperation between gene encoding p53 tumour antigen and RAS in cellular transformation, Nature, 312, 649, 10.1038/312649a0 · DOI · Paper page
- Couinaud, 1954, [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver], Presse Med, 62, 709
- Charnsangavej, 2006, Selection of patients for resection of hepatic colorectal metastases: expert consensus statement, Ann Surg Oncol, 13, 1261, 10.1245/s10434-006-9023-y · DOI · Paper page
- Neskey, 2015, Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer, Cancer Res, 75, 1527, 10.1158/0008-5472.CAN-14-2735 · DOI · Paper page
- Overman, 2016, Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials, Ann Oncol, 27, 1068, 10.1093/annonc/mdw073 · DOI
- Yaeger, 2014, BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer, Cancer, 120, 2316, 10.1002/cncr.28729 · DOI · Paper page
- Bazan, 2005, Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study, Ann Oncol, 16, iv50, 10.1093/annonc/mdi908 · DOI
- Ince, 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab, J Natl Cancer Inst, 97, 981, 10.1093/jnci/dji174 · DOI · Paper page
- Garcia-Aguilar, 2011, Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer, Ann Surg, 254, 486, 10.1097/SLA.0b013e31822b8cfa · DOI · Paper page
- Yamashita, 2017, APC and PIK3CA mutational cooperativity predicts pathologic response and survival in patients undergoing resection for colorectal liver metastases, Ann Surg
- Loupakis, 2015, Primary tumor location as a prognostic factor in metastatic colorectal cancer, J Natl Cancer Inst, 107, 10.1093/jnci/dju427 · DOI · Paper page
- Yamashita, 2016, Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases, Ann Surg
- Naccarati, 2012, Mutations and polymorphisms in TP53 gene: an overview on the role in colorectal cancer, Mutagenesis, 27, 211, 10.1093/mutage/ger067 · DOI
- Vakiani, 2012, Comparative genomic analysis of primary versus metastatic colorectal carcinomas, J Clin Oncol, 30, 2956, 10.1200/JCO.2011.38.2994 · DOI · Paper page
Cited by
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Colorectal liver metastases: Current management and future perspectives
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 275
Survival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
Self-citationGenetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
Metadata
- Authors
- Chun, Y. S., Passot, G., Yamashita, S., Nusrat, M., Katsonis, P., Loree, J. M., Conrad, C., Tzeng, C.-W. D., Xiao, L., Aloia, T. A., Eng, C., Kopetz, S. E., Lichtarge, O., & Vauthey, J.-N.
- Venue
- Annals of Surgery
- Published
- 2019-05
- Volume
- 269
- Issue
- 5
- Pages
- 917-923
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W2740497784
- Cited by
- 167
- References
- 6
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. https://app.cochat.ai/papers/10.1097/sla.0000000000002450
- The paper
- Chun, Y. S., Passot, G., Yamashita, S., Nusrat, M., Katsonis, P., Loree, J. M., Conrad, C., Tzeng, C.-W. D., Xiao, L., Aloia, T. A., Eng, C., Kopetz, S. E., Lichtarge, O., & Vauthey, J.-N. (2019). Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.